Literature DB >> 12142034

Missing HLA class I expression on Daudi cells unveils cytotoxic and proliferative responses of human gammadelta T lymphocytes.

Simon Rothenfusser1, Armin Buchwald, Sylvia Kock, Soldano Ferrone, Paul Fisch.   

Abstract

The major subset of human blood gammadelta T lymphocytes expresses the variable-region genes Vgamma9 and Vdelta2. These cells recognize non-peptidic phosphoantigens that are present in some microbial extracts, as well as the beta(2)-microglobulin-deficient Burkitt's lymphoma Daudi. Most cytotoxic human Vgamma9/Vdelta2 T cells express inhibitory natural killer cell receptors for HLA class I that downmodulate the responses of the gammadelta T lymphocytes against HLA class I expressing cells. In this study we show that transfection of the human beta(2)-microglobulin cDNA into Daudi cells markedly inhibits the cytotoxic and proliferative responses of human Vgamma9/Vdelta2 T cells. This provides direct evidence that the "innate" specificity of human Vgamma9/Vdelta2 T-lymphocytes for Daudi cells is uncovered by the loss of beta(2)m by Daudi. However, Daudi cells that express HLA class I in association with mouse beta(2)m at the cell surface are recognized by human Vgamma9/Vdelta2 T cells close to the same degree as the parental HLA class I deficient Daudi cell line. Thus, proper conformation of the HLA class I molecules is required for binding to natural killer cell receptors. Cloning of the HLA class I A, B, and C molecules of Daudi cells and transfer of the individual HLA class I molecules of Daudi cells into the HLA class I deficient recipient cell lines.221 and C1R demonstrate that for some human gammadelta T-cell clones cytolysis can be entirely inhibited by single HLA class I alleles while for other clones single HLA class I alleles only partially inhibit cytotoxicity. Thus, most human Vgamma9/Vdelta2 T cells represent a population of killer cells that evolved like NK cells to destroy target cells that have lost expression of individual HLA class I molecules but with a specificity that is determined by the Vgamma9/Vdelta2 TCR.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12142034     DOI: 10.1016/s0008-8749(02)00001-1

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells.

Authors:  Matthias Eberl; Hassan Jomaa; Adrian C Hayday
Journal:  Immunology       Date:  2004-07       Impact factor: 7.397

2.  miR-125b-5p and miR-99a-5p downregulate human γδ T-cell activation and cytotoxicity.

Authors:  Yuli Zhu; Siya Zhang; Zinan Li; Huaishan Wang; Zhen Li; Yu Hu; Hui Chen; Xuan Zhang; Lianxian Cui; Jianmin Zhang; Wei He
Journal:  Cell Mol Immunol       Date:  2018-02-12       Impact factor: 11.530

3.  Vav1-phospholipase C-γ1 (Vav1-PLC-γ1) pathway initiated by T cell antigen receptor (TCRγδ) activation is required to overcome inhibition by ubiquitin ligase Cbl-b during γδT cell cytotoxicity.

Authors:  Shanshan Yin; Jianmin Zhang; Yujia Mao; Yu Hu; Lianxian Cui; Ning Kang; Wei He
Journal:  J Biol Chem       Date:  2013-07-29       Impact factor: 5.157

4.  Flanking V and J sequences of complementary determining region 3 of T cell receptor (TCR) δ1 (CDR3δ1) determine the structure and function of TCRγ4δ1.

Authors:  Yan Jiang; Yang Guo; Xueyan Xi; Lianxian Cui; Wei He
Journal:  J Biol Chem       Date:  2011-05-23       Impact factor: 5.157

5.  Anti-leukemia activity of human gamma delta T cells.

Authors:  Gabrielle M Siegers
Journal:  Oncoimmunology       Date:  2012-03-01       Impact factor: 8.110

6.  RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.

Authors:  Dennis C Harrer; Bianca Simon; Shin-Ichiro Fujii; Kanako Shimizu; Ugur Uslu; Gerold Schuler; Kerstin F Gerer; Stefanie Hoyer; Jan Dörrie; Niels Schaft
Journal:  BMC Cancer       Date:  2017-08-17       Impact factor: 4.430

7.  Loss of nonclassical MHC molecules MIC-A/B expression during progression of uveal melanoma.

Authors:  C S Vetter; W Lieb; E-B Bröcker; J C Becker
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.